Ryvu Therapeutics Halts POTAMI-61 Myelofibrosis Trial
Key Insights
Ryvu Therapeutics SA has terminated its Phase 2 POTAMI-61 study of RVU120 in intermediate- or high-risk primary or secondary myelofibrosis (search).
The open-label trial tested oral RVU120 as monotherapy and combined with the JAK inhibitor ruxolitinib, with no placebo arm and non-random allocation.
The study record, first submitted 2024-04-29 and last updated 2026-09-15, is now listed as terminated before planned completion, pressuring the blood cancer pipeline.
Ryvu Therapeutics SA (DE:9Y4) has reported that its POTAMI-61 study, an open-label Phase 2 trial of RVU120 in myelofibrosis (search), is now listed as terminated. The trial was titled "An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)" and was designed to assess the efficacy and safety of RVU120 in a high-need cancer segment where current options often fall short.
The study evaluated RVU120, an oral targeted drug, both alone and together with ruxolitinib, a standard JAK inhibitor in myelofibrosis (search). It aimed to determine whether RVU120 could improve outcomes for patients who could not use JAK drugs or were not receiving sufficient benefit from them. The design used two parallel groups with no placebo arm, so all patients received active treatment; allocation was non-random and the trial was open-label, with treatment benefit as the main focus.
The trial record was first submitted on 2024-04-29, and the last update was filed on 2026-09-15, after which the status shifted to "terminated," signaling that the program as structured stopped before planned completion. The termination is a clear setback for Ryvu Therapeutics, likely adding near-term pressure to the stock as investors reassess the value of the blood cancer pipeline, potentially increasing scrutiny versus peers developing myelofibrosis (search) drugs such as Incyte around ruxolitinib, and shifting investor focus to other Ryvu assets or partnerships. Further details are available on the ClinicalTrials portal.